This company has been marked as potentially delisted and may not be actively trading. Neuralstem (CUR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CUR vs. SRNE, NKGN, SQZ, GNCAQ, GNCA, ELOX, PRME, PLX, IKT, and IZTCShould you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Sorrento Therapeutics (SRNE), NKGen Biotech (NKGN), SQZ Biotechnologies (SQZ), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Eloxx Pharmaceuticals (ELOX), Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), and Invizyne Technologies (IZTC). These companies are all part of the "medical" sector. Neuralstem vs. Its Competitors Sorrento Therapeutics NKGen Biotech SQZ Biotechnologies Genocea Biosciences Genocea Biosciences Eloxx Pharmaceuticals Prime Medicine Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies Neuralstem (NASDAQ:CUR) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Do insiders and institutionals hold more shares of CUR or SRNE? 38.3% of Neuralstem shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, CUR or SRNE? Neuralstem has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Does the media refer more to CUR or SRNE? In the previous week, Neuralstem's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score. Company Overall Sentiment Neuralstem Neutral Sorrento Therapeutics Neutral Is CUR or SRNE more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Sorrento Therapeutics' return on equity of 0.00% beat Neuralstem's return on equity.Company Net Margins Return on Equity Return on Assets Neuralstem-39,417.64% -170.51% -110.16% Sorrento Therapeutics N/A N/A N/A Which has better earnings and valuation, CUR or SRNE? Neuralstem has higher earnings, but lower revenue than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuralstem$260K14.05-$4.93MN/AN/ASorrento Therapeutics$60.32M0.05-$572.84MN/AN/A SummaryNeuralstem beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks. Get Neuralstem News Delivered to You Automatically Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CUR vs. The Competition Export to ExcelMetricNeuralstemBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.65M$347.55M$6.23B$10.66BDividend YieldN/AN/A5.71%4.82%P/E RatioN/AN/A30.2930.25Price / Sales14.05495.53595.12134.57Price / CashN/A22.4437.0161.44Price / Book0.263.7412.046.60Net Income-$4.93M-$133.30M$3.32B$276.82M Neuralstem Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CURNeuralstemN/A$1.74-1.7%N/A-52.8%$3.65M$260K0.006High Trading VolumeSRNESorrento Therapeutics1.0336 of 5 stars$0.01+40.0%N/A+140.0%$3.86M$60.32M0.00800High Trading VolumeNKGNNKGen BiotechN/A$0.02+100.0%N/A-94.8%$899KN/A0.00N/ASQZSQZ BiotechnologiesN/A$0.03+7.1%N/A+0.0%$885K$18.16M-0.011,620GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ELOXEloxx PharmaceuticalsN/AN/AN/AN/A$0.00N/A0.0030Gap DownPRMEPrime Medicine3.2239 of 5 stars$6.37+6.3%$8.92+40.0%+26.9%$857.24M$4.96M-3.11234Positive NewsGap UpHigh Trading VolumePLXProtalix BioTherapeutics2.1326 of 5 stars$2.49+5.1%$15.00+502.4%+129.1%$198.53M$61.95M-19.15200Gap UpIKTInhibikase Therapeutics1.3762 of 5 stars$1.60-1.2%$8.00+400.0%-38.9%$119.23MN/A-0.606News CoverageGap UpIZTCInvizyne TechnologiesN/A$12.99flatN/AN/A$81.21MN/A0.0029News Coverage Related Companies and Tools Related Companies SRNE Alternatives NKGN Alternatives SQZ Alternatives GNCAQ Alternatives GNCA Alternatives ELOX Alternatives PRME Alternatives PLX Alternatives IKT Alternatives IZTC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CUR) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuralstem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
